WallStreetZenWallStreetZen

NYSE: HUM
Humana Inc Stock

Overview
ForecastEarningsRevenueDividendOwnership
$263.61+4.69 (+1.81%)
Updated Apr 23, 2025
HUM Price
$263.61
Fair Value Price
N/A
Market Cap
$31.80B
52 Week Low
$213.31
52 Week High
$406.46
P/E
26.33x
P/B
1.94x
P/S
0.26x
PEG
1.16x
Dividend Yield
1.01%
Revenue
$117.76B
Earnings
$1.21B
Gross Margin
14.5%
Operating Margin
1.94%
Profit Margin
1%
Debt to Equity
1.83
Operating Cash Flow
$3B
Beta
0.45
Next Earnings
Apr 30, 2025
Ex-Dividend
Jun 27, 2025
Next Dividend
Jul 25, 2025

HUM Overview

Humana Inc. is a private health insurers in the U.S. with a focus on administering Medicare Advantage plans. The company specializes in government-sponsored programs, with nearly all its medical membership coming from individual and group Medicare Advantage, Medicaid programs, along with the military's Tricare program. Humana also offers prescription drug plans, employer-based plans, and other healthcare services. Humana was founded in 1961 and is headquartered in Louisville, KY.

Zen Rating

Our proven quant model uses 115 proprietary factors, including AI, to determine HUM's potential to beat the market

CHold
  • Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
View All “A” Zen Rated Stocks
→

Zen Rating Component Grades

B
Value
C
Growth
C
Momentum
B
Sentiment
C
Safety
C
Financials
C
Artificial Intelligence
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.

Industry: Healthcare Plan

Industry Rating
A
HUM
Ranked#7 of 10

Top Ranked Stocks in Industry

Name / TickerPriceZen Rating
Cigna Group (CI)
$336.69B
Centene (CNC)
$62.12B
Unitedhealth Group (UNH)
$427.96C
View Top Healthcare Plan Stocks

Be the first to know about important HUM news, forecast changes, insider trades & much more!

HUM News

Overview

Due Diligence Score

–
Industry Average (40)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how HUM scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

HUM ($263.61) is trading above its intrinsic value of $131.40, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
HUM is good value based on its earnings relative to its share price (26.33x), compared to the US market average (26.95x)
P/E vs Market Valuation
HUM is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more HUM due diligence checks available for Premium users.

Valuation

HUM price to earnings (PE)

For valuing profitable companies with steady earnings

Company
26.33x
Industry
23.83x
Market
26.95x
HUM is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
HUM is good value based... subscribe to Premium to read more.
P/E vs Market Valuation

HUM price to book (PB)

For valuing companies that are loss-making or have lots of physical asset

Company
1.94x
Industry
2.51x
HUM is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

HUM price to earnings growth (PEG)

For valuing profitable companies with growth potential

HUM is poor value relative... subscribe to Premium to read more.
PEG Value Valuation

HUM's financial health

Profit margin

Revenue
$29.2B
Net Income
-$693.0M
Profit Margin
-2.4%
HUM's Earnings (EBIT) of $2.28B... subscribe to Premium to read more.
Interest Coverage Financials
HUM's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$46.5B
Liabilities
$30.0B
Debt to equity
1.83
HUM's short-term assets ($29.82B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
HUM's short-term assets ($29.82B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
HUM's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
HUM's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
-$528.0M
Investing
-$63.0M
Financing
-$2.3B
HUM's operating cash flow ($2.97B)... subscribe to Premium to read more.
Debt Coverage Financials

HUM vs Healthcare Plan Stocks

TickerZen RatingMarket Cap1d %P/EP/B
HUMC$31.80B+1.81%26.33x1.94x
CNCB$30.81B+3.14%9.81x1.17x
MOHC$18.43B+3.38%16.18x4.10x
ALHCC$3.51B+0.77%-27.31x35.16x
OSCRC$3.01B+3.53%109.18x2.97x
View Top Healthcare Plan Stocks

Humana Stock FAQ

What is Humana's quote symbol?

(NYSE: HUM) Humana trades on the NYSE under the ticker symbol HUM. Humana stock quotes can also be displayed as NYSE: HUM.

If you're new to stock investing, here's how to buy Humana stock.

What is the 52 week high and low for Humana (NYSE: HUM)?

(NYSE: HUM) Humana's 52-week high was $406.46, and its 52-week low was $213.31. It is currently -35.14% from its 52-week high and 23.58% from its 52-week low.

How much is Humana stock worth today?

(NYSE: HUM) Humana currently has 120,644,737 outstanding shares. With Humana stock trading at $263.61 per share, the total value of Humana stock (market capitalization) is $31.80B.

Humana stock was originally listed at a price of $20.75 in Dec 31, 1997. If you had invested in Humana stock at $20.75, your return over the last 27 years would have been 1,170.41%, for an annualized return of 9.87% (not including any dividends or dividend reinvestments).

How much is Humana's stock price per share?

(NYSE: HUM) Humana stock price per share is $263.61 today (as of Apr 23, 2025).

What is Humana's Market Cap?

(NYSE: HUM) Humana's market cap is $31.80B, as of Apr 24, 2025.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Humana's market cap is calculated by multiplying HUM's current stock price of $263.61 by HUM's total outstanding shares of 120,644,737.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.